Wetherby, United Kingdom

Avacta is a UK-based biopharmaceutical company developing novel cancer immunotherapeutics and high performing diagnostics, based on its two proprietary platforms: Affimer and pre|CISION.


Investment Perspective

Avacta’s proprietary pre|CISION platform is key to the investment case, and further details on lead programme AVA6000, a tumour targeted form of the chemotherapy doxorubicin, continue to support key hypotheses. Data show that AVA6000 is selectively activated at the target tumour site, resulting in lower toxicities, improved tolerability, and greater potency. This has translated into promising, albeit early, signs of clinical activity. AVA6000’s clinical success will help to validate pre|CISION, and could unlock an extensive opportunity to repurpose a range of proven, but currently sub-optimal, therapies, and alongside the Affimer platform, could be used in novel diagnostic and therapeutic applications. AVA6000 has now completed the seventh, and final, cohort of the Phase Ia three-weekly arm, with patient screening started in the two-weekly arm in the US. Data will direct the format of a potentially pivotal Phase II trial. News over the next 18-24 months should offer multiple value-inflection points. Our updated valuation including the Coris acquisition is £672m (237p/share).

Market information

SymbolPrimary exchanges


Tailored tumour targetting with pre|CISION
Update | 14 Dec 2023
Momentum builds in Diagnostics and Therapeutics
Lighthouse | 28 Sep 2023
Diagnostics build-out continues with Coris acquisition
Lighthouse | 01 Jun 2023

Recent News

Appointment of Chief Business Officer
19 Dec 2023
AVA6000 Phase 1a safety study data
13 Dec 2023
Shareholder update to review AVA6000 Phase 1a data
04 Dec 2023
Presentation at AACR-NCI-EORTC conference
05 Oct 2023